{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:02:52Z","timestamp":1789740172879,"version":"4.0.1"},"reference-count":8,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1136\/bmjonc-2026-001255","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:15:26Z","timestamp":1789737326000},"page":"e001255","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Decentralised oncology trials: decentralisation as a tool, not the goal"],"prefix":"10.1136","volume":"5","author":[{"given":"Jordan E","family":"Cohen","sequence":"first","affiliation":[{"name":"Calvary Mater Newcastle, Waratah, NSW, Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Taylor","sequence":"additional","affiliation":[{"name":"Implementation to Impact (i2i), School of Population Health, University of New South Wales Medicine & Health, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"Westmead Applied Research Centre, Westmead Hospital, Westmead, NSW, Australia"},{"name":"Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-6516","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia"},{"name":"The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia"},{"name":"Garvan Institute of Medical Research, Sydney, NSW, Australia"},{"name":"ProCan, Children\u2019s Medical Research Institute, Faculty of Medicine & Health, University of Sydney, Westmead, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091806152273000_5.2.e001255.1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaoncol.2023.6565","article-title":"Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access","volume":"10","author":"Underhill","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026091806152273000_5.2.e001255.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2026-001145","article-title":"Decentralised Oncology Trials in the UK: Evidence, Regulation and Academic Clinical Trials Units\u2019 Perspectives","volume":"5","author":"Akala","year":"2026","journal-title":"BMJ Oncol"},{"key":"2026091806152273000_5.2.e001255.3","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae050","article-title":"Advancing clinical trial equity through integration of telehealth and decentralized treatment","volume":"8","author":"Brown","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"2026091806152273000_5.2.e001255.4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s43441-024-00665-y","article-title":"Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: \u201cIt\u2019s About Time we Bring Trials to People\u201d","volume":"58","author":"Richards","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"2026091806152273000_5.2.e001255.5","first-page":"67","article-title":"A questionnaire-based survey investigating patient and healthcare professionals\u2019 perspectives on telemedicine and remote clinical trials in oncology","volume":"31","author":"Kawakami","year":"2026","journal-title":"J Jpn Soc Clin Trial Res"},{"key":"2026091806152273000_5.2.e001255.6","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: Guideline for Good Clinical Practice E6(R3); 2025."},{"key":"2026091806152273000_5.2.e001255.7","unstructured":"Health Research Authority . Decentralised trial methods position statement. 2026."},{"key":"2026091806152273000_5.2.e001255.8","unstructured":"US Food and Drug Administration . Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties. 2024."}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2026-001255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:15:28Z","timestamp":1789737328000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2026-001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjonc-2026-001255"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2026-001255","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}